Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.

@article{Hohaus2010AnemiaIH,
  title={Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.},
  author={Stefan Hohaus and Giuseppina Massini and Manuela Giachelia and Barbara Vannata and Valentina Bozzoli and Annarosa Cuccaro and Francesco D'Alo' and Luigi Maria Larocca and Reinier A. P. Raymakers and Dorine W Swinkels and Maria Teresa Voso and Giuseppe Leone},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 15},
  pages={
          2538-43
        }
}
  • S. Hohaus, G. Massini, +9 authors G. Leone
  • Published 20 May 2010
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Cytokines play a pivotal role in Hodgkin's lymphoma (HL). Because interleukin-6 (IL-6) induces expression of hepcidin, one of the principal regulators of iron metabolism, we studied the contribution of hepcidin in anemia in HL at diagnosis. PATIENTS AND METHODS Plasma samples from 65 patients with HL were analyzed for hepcidin levels using a combination of weak cation exchange chromatography and time-of-flight mass spectrometry; cytokine levels were analyzed using enzyme-linked… 
View on PubMed
repository.ubn.ru.nl
93 Citations
Highly Influential Citations
2
Background Citations
31
Methods Citations
1
Results Citations
1

93 Citations

Citation Type

Citation Type

Serum hepcidin-25 level linked with high mortality in patients with non-Hodgkin lymphoma
TLDR
In this study, the group with higher hepcidin-25 levels manifested advanced anemia and poor survival in anemic patients with non-Hodgkin lymphoma, and the association between serum hePCid in-25 and mortality was analyzed using both the Kaplan-Meier method and a multivariate proportional hazards regression model.
Evaluation of Interleukin- 6 in Lymphoma
TLDR
IL-6 level was elevated in lymph cancer and it was significantly higher in lymphoma patients and the adverse impact of elevated IL-6 is consistent with demonstration of higher level of IL- 6 in patients with advanced stage of disease.
Anemia in lymphoma: interleukin-6, hepcidin and erythropoietin
TLDR
The clinical characteristics of the anemias of chronic infl ammation are similar to anemia found in cancer, and since several tumor types are associated with increased cytokine production, especially that of IL-6, hepcidin has been addressed as an explanation for the associated anemia in these conditions.
Iron in Hodgkin's lymphoma.
TLDR
Iron-restricted anemia at HL diagnosis can be aggravated by intensive chemotherapy, and iron overload may become clinically relevant in heavily treated patients with relapsed or refractory disease undergoing high-dose chemotherapy and stem cell transplantation.
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin
TLDR
It is suggested that elevated hepcidin levels and inadequate erythropoietin response are frequent in DLBCL, but elevated IL-6 plays the major role for the development of anemia.
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.
TLDR
The results of this study implicate hepcidin as a contributor to anemia in WM, and suggest that an iron re-utilization defect accompanies hePCidin overproduction leading to its sequestration in WM patients.
Clinical significance of serum IL-6, TNF-a, Hepcidin, and EPO levels in anaemia of chronic disease and iron deficiency anaemia: The laboratory indicators for anaemia
TLDR
Ferritin is the most valuable parameter for making the differential diagnose of anemia of chronic disease and iron deficiency anemia, in anemic patients but in some situations that ferritin cannot help for makingThe differential diagnose, interleukin-6 and erythropoietin may be useful for making a differential diagnose.
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
TLDR
The rates of anemia increase significantly during anti-cancer treatment and appear to be largely associated with iron deficiency.
Aspects of the pathogenesis of anemia in cancer patients
TLDR
Understanding of the factors involved in the pathogenesis of anemia in cancer patients will allow the clinical physician to choose a rational way of pathogenetic or substitution correction of anemic syndrome, taking into account the personalized approach to treatment and prevention.
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
TLDR
The findings indicate that LY2787106 was well tolerated in cancer patients with anemia and that targeting the hepcidin-ferroportin pathway by neutralizing hePCidin resulted in transient iron mobilization, thus supporting the role of he pcidin in iron regulation.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Involvement of Hepcidin in the Anemia of Multiple Myeloma
TLDR
Results indicate hepcidin is up-regulated in multiple myeloma patients by both IL-6-dependent and IL- 6-independent mechanisms and may play a role in the anemia of multipleMyeloma.
Role of cytokines in the response to erythropoietin in hemodialysis patients.
TLDR
A previously undescribed pattern of cytokine alteration that is relevant to determine increased needs of EPO in hemodialysis patients is disclosed and has potential applicability in designing strategies to improve EPO resistance.
Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.
TLDR
In vivo human results confirm the importance of the IL-6-hepcidin axis in the development of hypoferremia in inflammation and highlight the rapid responsiveness of this iron regulatory system.
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.
TLDR
The linkage of hepcidin induction to inflammation in humans supports its proposed role as a key mediator of anemia of inflammation.
Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler’s syndrome treated with IL-1 receptor antagonist
TLDR
This in vivo human model supports the importance of an HFE-independent IL-6-hepcidin axis in the development of hypoferremia and anemia of inflammation and suggests that chronic inflammation protects patients with H FE-related hereditary hemochromatosis from iron accumulation.
Hepcidin and Cytokines in Anaemia
  • R. Means
  • Medicine, Biology
    Hematology
  • 2004
TLDR
Hepcidin appears to be a major factor in the systemic iron abnormalities seen in ACD; whether it contributes to the other aspects of the pathogenesis of the syndrome requires further investigation.
Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients.
TLDR
A potential role of hepcidin serum concentrations in predicting the response to epoetin therapy in anemic cancer patients is suggested.
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.
TLDR
Human hepcidin, a 25-amino acid peptide made by hepatocytes, may be a new mediator of innate immunity and the long-sought iron-regulatory hormone and its role in iron metabolism could lead to new therapies for hemochromatosis and anemia of inflammation.
Serum YKL-40 and Interleukin 6 Levels in Hodgkin Lymphoma
TLDR
Serum levels of the inflammatory markers YKL-40 and IL-6 levels were increased in untreated Hodgkin lymphoma patients and those with more advanced stages but did not differ significantly by Hodgkins lymphoma histology.
Iron metabolism in the anemia of chronic disease.
  • G. Weiss
  • Biology, Medicine
    Biochimica et biophysica acta
  • 2009
...
1
2
3
4
5
...